British Journal of Cancer .Phase I–II Study of Plitidepsin and Dacarbazine as First-Line Therapy For Advanced Melanoma .
R Plummer, P Lorigan, E Brown, R Zaucha, V Moiseyenko, L Demidov, V Soriano, E Chmielowska, R Andrés, G Kudryavtseva, C Kahatt, S Szyldergemajn, S Extremera, B de Miguel, M Cullell-Young and H Calvert
AbstractBackground:
This phase I–II trial compared plitidepsin 1-h infusion alone or combined with dacarbazine (DTIC) 1-h infusion as front-line therapy for advanced melanoma.
... The overall response rate with plitidepsin/DTIC was 21.4%; all responders had normal serum lactate dehydrogenase (LDH) levels and performance status 1 at baseline.
... Conclusion:
This plitidepsin/DTIC schedule has antitumour activity and manageable toxicity in advanced melanoma. Further evaluation of plitidepsin 2.4 mg m−2 fortnightly and DTIC 800 mg m−2 q4wk is recommended.
...